215 related articles for article (PubMed ID: 19587004)
1. Processing of two latent membrane protein 1 MHC class I epitopes requires tripeptidyl peptidase II involvement.
Diekmann J; Adamopoulou E; Beck O; Rauser G; Lurati S; Tenzer S; Einsele H; Rammensee HG; Schild H; Topp MS
J Immunol; 2009 Aug; 183(3):1587-97. PubMed ID: 19587004
[TBL] [Abstract][Full Text] [Related]
2. Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells.
Kobayashi H; Nagato T; Takahara M; Sato K; Kimura S; Aoki N; Azumi M; Tateno M; Harabuchi Y; Celis E
Cancer Res; 2008 Feb; 68(3):901-8. PubMed ID: 18245493
[TBL] [Abstract][Full Text] [Related]
3. Epstein-Barr virus (EBV) latent membrane protein-1-specific cytotoxic T lymphocytes targeting EBV-carrying natural killer cell malignancies.
Demachi-Okamura A; Ito Y; Akatsuka Y; Tsujimura K; Morishima Y; Takahashi T; Kuzushima K
Eur J Immunol; 2006 Mar; 36(3):593-602. PubMed ID: 16479544
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of serine-peptidase activity enhances the generation of a survivin-derived HLA-A2-presented CTL epitope in colon-carcinoma cells.
Preta G; Marescotti D; Fortini C; Carcoforo P; Castelli C; Masucci M; Gavioli R
Scand J Immunol; 2008 Dec; 68(6):579-88. PubMed ID: 19000094
[TBL] [Abstract][Full Text] [Related]
5. Three immunoproteasome-associated subunits cooperatively generate a cytotoxic T-lymphocyte epitope of Epstein-Barr virus LMP2A by overcoming specific structures resistant to epitope liberation.
Ito Y; Kondo E; Demachi-Okamura A; Akatsuka Y; Tsujimura K; Tanimoto M; Morishima Y; Takahashi T; Kuzushima K
J Virol; 2006 Jan; 80(2):883-90. PubMed ID: 16378990
[TBL] [Abstract][Full Text] [Related]
6. No essential role for tripeptidyl peptidase II for the processing of LCMV-derived T cell epitopes.
Basler M; Groettrup M
Eur J Immunol; 2007 Apr; 37(4):896-904. PubMed ID: 17357105
[TBL] [Abstract][Full Text] [Related]
7. Role of tripeptidyl peptidase II in MHC class I antigen processing - the end of controversies?
Endert Pv
Eur J Immunol; 2008 Mar; 38(3):609-13. PubMed ID: 18286570
[TBL] [Abstract][Full Text] [Related]
8. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes.
Khanna R; Burrows SR; Nicholls J; Poulsen LM
Eur J Immunol; 1998 Feb; 28(2):451-8. PubMed ID: 9521052
[TBL] [Abstract][Full Text] [Related]
9. Processing of a multiple membrane spanning Epstein-Barr virus protein for CD8(+) T cell recognition reveals a proteasome-dependent, transporter associated with antigen processing-independent pathway.
Lautscham G; Mayrhofer S; Taylor G; Haigh T; Leese A; Rickinson A; Blake N
J Exp Med; 2001 Oct; 194(8):1053-68. PubMed ID: 11602636
[TBL] [Abstract][Full Text] [Related]
10. Rescue of the immunotherapeutic potential of a novel T cell epitope in the Epstein-Barr virus latent membrane protein 2.
Lalonde A; Avila-Cariño J; Caruso M; de Campos-Lima PO
Virology; 2007 May; 361(2):253-62. PubMed ID: 17207511
[TBL] [Abstract][Full Text] [Related]
11. The efficiency of human cytomegalovirus pp65(495-503) CD8+ T cell epitope generation is determined by the balanced activities of cytosolic and endoplasmic reticulum-resident peptidases.
Urban S; Textoris-Taube K; Reimann B; Janek K; Dannenberg T; Ebstein F; Seifert C; Zhao F; Kessler JH; Halenius A; Henklein P; Paschke J; Cadel S; Bernhard H; Ossendorp F; Foulon T; Schadendorf D; Paschen A; Seifert U
J Immunol; 2012 Jul; 189(2):529-38. PubMed ID: 22706083
[TBL] [Abstract][Full Text] [Related]
12. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
[TBL] [Abstract][Full Text] [Related]
13. Role of tripeptidyl peptidase II in the processing of Listeria monocytogenes-derived MHC class I-presented antigenic peptides.
Grauling-Halama S; Bahr U; Schenk S; Geginat G
Microbes Infect; 2009; 11(8-9):795-802. PubMed ID: 19426827
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
[TBL] [Abstract][Full Text] [Related]
15. Need for tripeptidyl-peptidase II in major histocompatibility complex class I viral antigen processing when proteasomes are detrimental.
Guil S; Rodríguez-Castro M; Aguilar F; Villasevil EM; Antón LC; Del Val M
J Biol Chem; 2006 Dec; 281(52):39925-34. PubMed ID: 17088258
[TBL] [Abstract][Full Text] [Related]
16. Role of LMP1 in immune control of EBV infection.
Pai S; Khanna R
Semin Cancer Biol; 2001 Dec; 11(6):455-60. PubMed ID: 11669607
[TBL] [Abstract][Full Text] [Related]
17. Tripeptidyl peptidase II is dispensable for the generation of both proteasome-dependent and proteasome-independent ligands of HLA-B27 and other class I molecules.
Marcilla M; Villasevil EM; de Castro JA
Eur J Immunol; 2008 Mar; 38(3):631-9. PubMed ID: 18286573
[TBL] [Abstract][Full Text] [Related]
18. An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope.
Seifert U; Marañón C; Shmueli A; Desoutter JF; Wesoloski L; Janek K; Henklein P; Diescher S; Andrieu M; de la Salle H; Weinschenk T; Schild H; Laderach D; Galy A; Haas G; Kloetzel PM; Reiss Y; Hosmalin A
Nat Immunol; 2003 Apr; 4(4):375-9. PubMed ID: 12598896
[TBL] [Abstract][Full Text] [Related]
19. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants.
van Hall T; Wolpert EZ; van Veelen P; Laban S; van der Veer M; Roseboom M; Bres S; Grufman P; de Ru A; Meiring H; de Jong A; Franken K; Teixeira A; Valentijn R; Drijfhout JW; Koning F; Camps M; Ossendorp F; Kärre K; Ljunggren HG; Melief CJ; Offringa R
Nat Med; 2006 Apr; 12(4):417-24. PubMed ID: 16550190
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitors reconstitute the presentation of cytotoxic T-cell epitopes in Epstein-Barr virus-associated tumors.
Gavioli R; Vertuani S; Masucci MG
Int J Cancer; 2002 Oct; 101(6):532-8. PubMed ID: 12237893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
